An old drug finds a new use
Dr. Anglea Wandinger-Ness and Dr. Laurie Hudson were awarded a Provocative Questions grant to investigate the use of R-ketorolac against ovarian cancer. Ketorolac is an NSAID that the FDA approved for human use in 1991. They are investigating their hypothesis that R-ketorolac, and not S-ketorolac, acts on GTPases in the cell to control cell adhesion and growth in ovarian cancer cells.
Most drugs take ten years—and frequently, more—to go from concept to FDA approval. One way to reduce this time investment is to look for already-approved drugs that could be put to new uses. And that's just what Angela Wandinger-Ness, PhD, UNM Professor of Pathology, and Laurie Hudson, PhD, UNM Professor of Pharmaceutical Sciences, have done. Drs. Wandinger-Ness and Hudson, both at the University of New Mexico Cancer Center, were recently awarded a two-year exploratory National Cancer Institute (NCI) grant to investigate the use of R-ketorolac against ovarian cancer cells.
Ketorolac is an NSAID, or non-steroidal anti-inflammatory drug. The FDA approved its use for pain relief in humans in 1991. "Inflammation is an important process in cancer," says Dr. Hudson. Dr. Wandinger-Ness adds, "So the provocative question is: why? Why are some NSAIDs protective in cancer, while others are not? What are the protective mechanisms, anti-inflammatory or other basis? We know that NSAIDs work, but lack a complete understanding of the basis of anti-cancer efficacy."
In fact, several areas in cancer research are not well understood. So to consider some of these areas now that new technologies can be used to explore them, the NCI created a list of 24 Provocative Questions and awarded grants in these areas. Dr. Wandinger-Ness and Dr. Hudson are two of only 57 Provocative Questions grant recipients. Their work centers on demonstrating one path by which anti-inflammatory drugs can protect against cancer.
Dr. Wandinger-Ness's work with GTPases—the chemical switches inside a cell which regulate processes ranging from cell growth to how cells adhere to each other—dovetailed nicely with Dr. Hudson's work on how ovarian cancer spreads. They have been collaborating now for over 5 years. Their collaboration also synergizes with the work of other researchers—"Team Science," as Dr. Wandinger-Ness calls it.
Capitalizing on the flow cytometry expertise of Larry Sklar, PhD, UNM Professor of Pathology, and the drug conformation computer modeling expertise of Tudor Oprea, MD, PhD, UNM Professor of Biochemistry and Molecular Biology (both at UNM Cancer Center), Dr. Wandinger-Ness and Dr. Hudson identified drugs they thought would control GTPases in a cell. The process was similar to finding the proverbial needle in the haystack. "Technologies like flow cytometry and advanced computer modeling allow this kind of discovery to be made," says Dr. Hudson.
The first drug the team found, R-naproxen, was FDA approved but not available for human use so they found a second candidate, R-ketorolac. Now, working with Jennifer Golden, PhD, Assistant Director at the Kansas University Specialized Chemistry Center, they are precisely targeting particular types of GTPases in a cell to modulate cancer cell behaviors that affect tumor growth and spread. Their many experiments and initial animal studies using R-ketorolac against ovarian cancer look very promising in keeping tumor growth in check.
R-naproxen and R-ketorolac are not anti-inflammatory agents, though. While their mirror images, S-naproxen and S-ketorolac, target a specific class of proteins called cyclooxygenases that strongly inhibit inflammation—making them potent NSAIDs—R-naproxen and R-ketorolac do not have these properties. It's a provocative twist to Provocative Question number 5 on the NCI's list.
Ketorolac is marketed as Toradol for post-operative pain and consists of an R-ketorolac and S-ketorolac mixture allowing both forms of the drug to be administered in a single dose. Although both forms have exactly the same chemical formula, they are not the same molecule in three dimensions just as your left hand and your right hand are not the same. Thus, they behave differently inside a cell because the drugs interact with different proteins just as "the right hand only fits a right hand glove, but doesn't fit into the left hand glove," as Dr. Hudson explains.
Dr. Wandinger-Ness and Dr. Hudson are now proposing that R-ketorolac has a possible new activity inside the cell. "We think R-ketorolac interacts with the GTPases," says Dr. Wandinger-Ness. GTPases control cell growth and cell adherence, two important characteristics of ovarian cancer cells. "We have good of evidence that R-naproxen interacts with this GTPase pathway," Dr. Hudson says. So now, through their NCI grant, they're working to demonstrate that R-ketorolac can inhibit the specific GTPase cascades that enable ovarian cancer cell behaviors contributing to tumor growth and spread.
Dr. Wandinger-Ness and Dr. Hudson along with Carolyn Muller, MD, UNM Professor of Obstetrics and Gynecologic Oncology, want to expand these studies to benefit people. That's why, through several other grants, they intend to begin Phase I clinical trials of R-ketorolac for ovarian cancer. "Building something like this requires a long time and it requires seed money," says Dr. Wandinger-Ness. "We want to acknowledge cancer donors and the UNM Cancer Center grant." Through this complex network of scientific teamwork and funding, they'll be able to bring this research to the clinic far faster than any new drug to the marketplace.
Provided by University of New Mexico Cancer Center
- Non-narcotic pain medication is safe and effective after sinus surgery Mar 23, 2012 | not rated yet | 0
- Researchers find drug duo kills chemotherapy-resistant ovarian cancer cells Dec 07, 2011 | not rated yet | 0
- Ovarian cancer cells hijack surrounding tissues to enhance tumor growth Sep 04, 2012 | not rated yet | 0
- New treatment to overpower drug resistance in ovarian cancer Nov 15, 2010 | not rated yet | 0
- Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth Apr 15, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications May 23, 2013 | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications May 23, 2013 | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications May 22, 2013 | not rated yet | 0
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications May 22, 2013 | not rated yet | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
15 hours ago | 5 / 5 (3) | 0 |
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
10 hours ago | 3 / 5 (2) | 0 |
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
12 hours ago | 3.7 / 5 (3) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
13 hours ago | 5 / 5 (4) | 0 |
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
15 hours ago | 4 / 5 (2) | 2
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
9 hours ago | not rated yet | 0